Hot Features
프리미엄
Chromocell Therapeutics Corporation (CHRO)
AMEX
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. I... Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. 더 보기
FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American:...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.025 | -2.63157894737 | 0.95 | 0.95 | 0.7511 | 4266 | 0.89634318 | CS |
| 4 | 0.165 | 21.7105263158 | 0.76 | 0.95 | 0.6571 | 12168 | 0.84341319 | CS |
| 12 | -0.436 | -32.0352681852 | 1.361 | 1.75 | 0.585 | 27534 | 1.07849083 | CS |
| 26 | -2.575 | -73.5714285714 | 3.5 | 3.68 | 0.585 | 24228 | 1.6205437 | CS |
| 52 | -5.075 | -84.5833333333 | 6 | 6 | 0.585 | 25218 | 1.99919547 | CS |
| 156 | -5.075 | -84.5833333333 | 6 | 6 | 0.585 | 25218 | 1.99919547 | CS |
| 260 | -5.075 | -84.5833333333 | 6 | 6 | 0.585 | 25218 | 1.99919547 | CS |
| 기호 | 가격 | 볼륨 |
|---|---|---|
| VHAIVocodia Holdings Corp | US$ 0.0269 (-15.94%) | 34.59M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 27.08 (-1.28%) | 30.9M |
| XLFFinancial Select Sector | US$ 44.215 (-1.64%) | 19.06M |
| SOXSDirexion Daily Semiconductor Bear 3X Shares New | US$ 29.40 (1.48%) | 16.41M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 7.815 (0.19%) | 14.61M |
Risk
2 분 전
Deportes
2 분 전
cintrix
2 분 전
BigBadWolf
2 분 전
bobby1151
2 분 전
Iggy_Bot
3 분 전
Aimless Blade
3 분 전
Moonboy1
3 분 전
Rainer
3 분 전
uranium-pinto-beans
3 분 전
stabile
3 분 전
Zorax
3 분 전
bas2020
3 분 전
Spence2388
3 분 전
jxyzobrien
3 분 전
DGJR
4 분 전
Stinger2014
4 분 전
Think1st
4 분 전
Nebuchadnezzar
4 분 전
excelsiorvision
4 분 전
1jas
4 분 전
johnydollar
4 분 전
Kb1123
4 분 전
al44
4 분 전
2B_unknown
5 분 전
